Targeting the interleukin-11 receptor, LASN01 is a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
Lassen Therapeutics announced new clinical and preclinical data involving LASN01, a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
These data were announced at the 2023 European Respiratory Society (ERS) International Congress and the 45th Annual Meeting of the European Thyroid Association (ETA).
Maria Fardis, PhD, MBA, the CEO at Lassen discussed presentations in a press release from the company.
“I am very excited about the prospective clinical indications enabled by blocking IL-11R in multiple fibro-inflammatory diseases,” said Fardis. “Toward that, we have made significant progress in generating data with LASN01 in both clinical and nonclinical settings. We have completed our Phase 1 single ascending and multiple ascending dose cohorts and presented data from our healthy volunteer study at ERS. We also presented our preclinical data in a TED fibro-inflammatory disease model using orbital fibroblasts (OF) at ETA. The OF data strongly support development of LASN01 in TED.”
According to a press release from Lassen, “OFs were obtained from healthy control and TED patients following orbital decompression surgery and were analyzed for IL-11 expression. IL-11 was elevated in unstimulated OF obtained from TED patients compared to control cells. The effects of IL-11R blockade with LASN01 on the release of HA, cell proliferation, and collagen expression, all drivers of TED progression, were examined in response to stimulation with IL-11 and other stimuli.”1
Furthermore, the company stated that IL-11 induced proliferation and secretion of HA in OF both can be inhibited by LASN01 addition. Also stating that LASN01 inhibited combination of IGF-1 and IL-11 stimulations of OFs. Thus, the company concluded that LASN01 worked effectively in combination with teprotumumab, an approved agent for the treatment of TED, in inhibiting HA release.1